Sei Investments Co. purchased a new position in Amneal Pharmaceuticals Inc (NYSE:AMRX) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 8,492 shares of the company’s stock, valued at approximately $139,000.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. First Mercantile Trust Co. bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at approximately $155,000. Cornerstone Wealth Management LLC bought a new stake in Amneal Pharmaceuticals during the second quarter worth approximately $595,000. Montag A & Associates Inc. bought a new stake in Amneal Pharmaceuticals during the second quarter worth approximately $164,000. Xact Kapitalforvaltning AB bought a new stake in Amneal Pharmaceuticals during the second quarter worth approximately $203,000. Finally, Public Employees Retirement Association of Colorado bought a new stake in Amneal Pharmaceuticals during the second quarter worth approximately $210,000. Hedge funds and other institutional investors own 32.41% of the company’s stock.
A number of brokerages recently commented on AMRX. Morgan Stanley began coverage on Amneal Pharmaceuticals in a research note on Monday, July 23rd. They issued an “overweight” rating and a $22.00 target price for the company. Canaccord Genuity restated a “hold” rating and issued a $21.00 target price on shares of Amneal Pharmaceuticals in a research note on Tuesday, September 4th. ValuEngine lowered Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 27th. B. Riley assumed coverage on Amneal Pharmaceuticals in a research report on Friday, June 22nd. They issued a “buy” rating and a $26.00 price target on the stock. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $35.00 price target on shares of Amneal Pharmaceuticals in a research report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $23.86.
Shares of AMRX stock traded up $0.16 during trading hours on Friday, hitting $18.81. 1,122,246 shares of the company’s stock were exchanged, compared to its average volume of 1,185,310. The stock has a market capitalization of $6.62 billion, a PE ratio of 29.86, a PEG ratio of 0.98 and a beta of 1.41. Amneal Pharmaceuticals Inc has a 52 week low of $13.47 and a 52 week high of $24.48. The company has a debt-to-equity ratio of 2.85, a quick ratio of 1.25 and a current ratio of 2.01.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings results on Thursday, August 9th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. The business had revenue of $462.33 million for the quarter, compared to analysts’ expectations of $460.82 million. Amneal Pharmaceuticals had a negative return on equity of 8.74% and a negative net margin of 52.94%. The business’s quarterly revenue was down 2.5% on a year-over-year basis. As a group, analysts forecast that Amneal Pharmaceuticals Inc will post 0.96 earnings per share for the current fiscal year.
In other news, CFO Bryan M. Reasons sold 11,698 shares of the firm’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total transaction of $276,657.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Nikita Shah sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $23.46, for a total value of $1,173,000.00. The disclosure for this sale can be found here. 3.20% of the stock is owned by company insiders.
Amneal Pharmaceuticals Profile
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Featured Article: Does the discount rate affect the economy?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.